Key figures
FY2025 (31 December 2025), if not indicated otherwise.
Financial Guidance
The figures of the guidance 2026 as mentioned below were calculated on the same basis as the actual figures for 2026 and based on current rules and regulations.
2026 Revenue
Low-teens % to mid-teens% (at CER)
(Raised from: High single‑digit % to low double-digit)
- Strong growth driven by BIMZELX®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY®, BRIVIACT®
- BIMZELX® access expansion & net pricing erosion
- Briviact LOE
2026 adj. EBITDA
Mid-teens % to low-twenties % (at CER)
(Raised from: High single‑digit % to low double-digit)
- Continued investment behind 5 growth drivers
- Pipeline advancement and integration of recent acquisition (Neurona Therapeutics and Candid Therapeutics)
- EVENITY contribution
FX impact
If 30-Jun-26 FX rates persist:
- ~ -2 ppts on revenue growth
- ~ -6 ppts on adjusted EBITDA growth
Product Sales
Strong launch execution & disciplined value creation in HY26
BRIVIACT®
peak sales guidance
≥ € 600 million by 2026
achieved ahead of time in 2024
FINTEPLA®
peak sales guidance
≥ € 800 million by 2027
BIMZELX®
peak sales guidancet
> € 7 billion
Cash Flows
Per June 2026, the evolution of cash flow generated by biopharmaceuticals activities is affected by the following:
- Cash flow from operating activities amounted to € 369 million, compared to € 711 million end of June 2025 and stemming from underlying net profitability, offset with higher working capital needs linked to the ongoing expansion and growth of UCB.
- Cash flow from investing activities showed an outflow of € 2 683 million, compared to an outflow of € 166 million in June 2025 and includes mainly the cash consideration paid for the acquisition of Neurona Therapeutics, Candid Therapeutics and the Patient Insight Business of IMIDomics.
- Cash flow from financing activities has an inflow of € 804 million, which includes the US$ 1 500 million bullet term loan facility as well as € 150 million that was drawn under the Revolving Credit Facility, both signed in the context of the acquisition of Candid Therapeutics, mainly offset by the dividend paid to UCB shareholders (€ 276 million), the acquisition of treasury shares (€ 127 million) as well as the voluntary prepayment of the euro Schuldscheindarlehen (SSD) transactions for a total amount of € 66 million and the € 90 million bilateral loan.
